Compare AAON & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAON | JAZZ |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 10.8B |
| IPO Year | N/A | 2007 |
| Metric | AAON | JAZZ |
|---|---|---|
| Price | $78.14 | $167.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $104.00 | ★ $199.20 |
| AVG Volume (30 Days) | 843.8K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | $1,315,577,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $18.10 | $6.00 |
| Revenue Next Year | $12.34 | $6.84 |
| P/E Ratio | $64.38 | ★ N/A |
| Revenue Growth | ★ 8.77 | 4.14 |
| 52 Week Low | $62.00 | $95.49 |
| 52 Week High | $137.90 | $182.99 |
| Indicator | AAON | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 29.65 | 57.75 |
| Support Level | $79.65 | $161.00 |
| Resistance Level | $84.59 | $168.69 |
| Average True Range (ATR) | 3.85 | 4.96 |
| MACD | -1.02 | -1.99 |
| Stochastic Oscillator | 3.51 | 30.32 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.